/OCGN

Ocugen Inc

OCGN

$1.02USD↓-0.49%-0.00 today

MARKET CAP

345.9M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$1 – $1

52W RANGE

$1

$3

AI Summary

Stalk

StalkMedium

OCGN remains in a Stage 2 advancing corrective reset with the active Bullish Pivot Point confirming structural repair. The recent volume-led breakout above resistance is positive, but price is extended above the rising 9/21 EMA zone and near overhead supply. Medium-term bias stays bullish in line with Stage 2, while short-term timing is unfavorable. We defer execution and stalk for a pullback into the supported EMA zone for cleaner entry. Primary risks include failure to hold the 9/21 EMA support and a reversal at the overhead resistance band.

↑Pivotal-stage gene therapy programs target retinitis pigmentosa and Stargardt disease for global approvals.
↑Planned BLA filings in 2027 with AMD therapy launch anticipated by 2028.
↓Q2 EPS loss of $0.07 and Q3 estimate of $0.06 reflect ongoing unprofitability.

Full analysis →

Buying

3

institutions

Selling

4

institutions

New Positions

0

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕	Action↕	Shares Held↕	Value↓	Change↕	Chg %↕	Weight↕
BI Blackrock, Inc. Q2 2026	BUY	27.00 M	41.31 M	+19.70 M	+212.5%	0.00%
MM Millennium Management LLC Q2 2026	BUY	14.37 M	21.98 M	+436.06 K	-12.8%	0.01%
CA Citadel Advisors LLC Q2 2026	SELL	1.08 M	1.66 M	+-2.10 M	-71.2%	0.00%
PA Point72 Asset Management, L.P. Q2 2026	SELL	477.82 K	731.07 K	+-356.67 K	-51.6%	0.00%
JC Jpmorgan Chase & Co Q2 2026	BUY	157.11 K	262.38 K	+146.24 K	+1278.5%	0.00%
RC Rockefeller Capital Management L.P. Q2 2026	SELL	75.00	115.00	+-9.00	-24.3%	0.00%
BH Brevan Howard Capital Management LP Q2 2026	SELL	0.00	0.00	+-448.16 K	-100.0%	0.00%